Patents by Inventor Marco Demaria

Marco Demaria has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190022090
    Abstract: Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.
    Type: Application
    Filed: August 3, 2018
    Publication date: January 24, 2019
    Inventors: Remi-Martin Laberge, Judith Campisi, Marco Demaria, Nathaniel David, Alain Philippe Vasserot, James L. Kirkland, Tamar Tchkonia, Yi Zhu, Darren J. Baker, Bennett G. Childs, Jan M.A. van Deursen
  • Publication number: 20190000846
    Abstract: Foamy macrophages with senescence markers accumulate in the subendothelial space at the onset of atherosclerosis where they drive pathology by increasing expression of key atherogenic and inflammatory cytokines and chemokines. This invention provides senolytic agents that remove senescent cells that are present in or around atherosclerotic plaques. The agents inhibit or reverse thinning of the fibrous cap on atherosclerotic plaques. This has the effect of stabilizing the plaques, inhibiting rupture and preventing pathological sequelae that manifest as coronary artery disease. Senolytic agents used in this way complement the action of statins and other drugs that cause plaque regression. Thus, senolytic agents and lipid lowering drugs can be used in combination for enhanced therapeutic effect.
    Type: Application
    Filed: July 2, 2018
    Publication date: January 3, 2019
    Inventors: Jan M.A. van Deursen, Bennett G. Childs, Darren J. Baker, James L. Kirkland, Tamar Tchkonia, Yi Zhu, Nathaniel David, Remi-Martin Laberge, Judith Campisi, Marco Demaria
  • Patent number: 10130628
    Abstract: This disclosure provides a technology for managing the sensation of pain in a subject in need thereof. Treatment methods according to this invention include administering to the subject a formulation that contains an effective amount of (4-[(4S,5R)-4,5-bis(4-chlorophenyl)-4,5-dihydro-2-[4-methoxy-2-(1-methylethoxy)phenyl]-1H-imidazol-1-yl]carbonyl]-2-piperazinone).
    Type: Grant
    Filed: April 6, 2017
    Date of Patent: November 20, 2018
    Assignees: UNITY BIOTECHNOLOGY, INC., BUCK INSTITUTE FOR RESEARCH ON AGING, THE JOHNS HOPKINS UNIVERSITY, MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
    Inventors: Nathaniel David, Albert Davalos, Remi-Martin Laberge, Judith Campisi, Marco Demaria, Alain Vasserot, Chaekyu Kim, Okhee Jeon, Jennifer Elisseeff, James L. Kirkland, Tamar Tchkonia, Yi Zhu
  • Publication number: 20180303828
    Abstract: Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.
    Type: Application
    Filed: June 13, 2018
    Publication date: October 25, 2018
    Inventors: Remi-Martin Laberge, Judith Campisi, Marco Demaria, Nathaniel David, Darren J. Baker, James L. Kirkland, Tamar Tchkonia, Yi Zhu, Jan M.A. van Deursen
  • Publication number: 20180256568
    Abstract: Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.
    Type: Application
    Filed: April 11, 2018
    Publication date: September 13, 2018
    Inventors: Remi-Martin Laberge, Judith Campisi, Albert Davalos, Marco Demaria, Nathaniel David, Alain Philippe Vasserot, Darren J. Baker, Bennett G. Childs, James L. Kirkland, Tamar Tchkonia, Jan M.A. van Deursen, Jennifer Elisseeff, Chaekyu Kim, Okhee Jeon, Allyson K. Palmer, Yi Zhu
  • Publication number: 20180235956
    Abstract: Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.
    Type: Application
    Filed: April 17, 2018
    Publication date: August 23, 2018
    Inventors: Remi-Martin Laberge, Judith Campisi, Marco Demaria, Nathaniel David, Darren J. Baker, James L. Kirkland, Tamar Tchkonia, Yi Zhu, Jan M.A. van Deursen
  • Publication number: 20180235957
    Abstract: Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.
    Type: Application
    Filed: April 18, 2018
    Publication date: August 23, 2018
    Inventors: Remi-Martin Laberge, Judith Campisi, Marco Demaria, Nathaniel David, Alain Philippe Vasserot, James L. Kirkland, Tamar Tchkonia, Yi Zhu, Darren J. Baker, Bennett G. Childs, Jan M.A. van Deursen
  • Publication number: 20180193458
    Abstract: Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders. Also included herein are methods for extending lifespan.
    Type: Application
    Filed: July 8, 2016
    Publication date: July 12, 2018
    Inventors: Jose Alberto Lopez-Dominguez, Remi-Martin Laberge, Judith Campisi, Albert Davalos, Marco Demaria, Nathaniel David, Alain Philippe Vasserot, Darren J. Baker, Bennett G. Childs, James L. Kirkland, Tamar Tchkonia, Jan M.A. van Deursen, Yi Zhu
  • Patent number: 10010546
    Abstract: Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.
    Type: Grant
    Filed: November 30, 2017
    Date of Patent: July 3, 2018
    Assignees: Unity Biotechnology, Inc., Buck Institute for Research on Aging, Mayo Foundation for Medical Education and Research
    Inventors: Remi-Martin Laberge, Judith Campisi, Marco Demaria, Nathaniel David, Alain Philippe Vasserot, James L. Kirkland, Tamar Tchkonia, Yi Zhu, Darren J. Baker, Bennett G. Childs, Jan M. A. van Deursen
  • Patent number: 9993472
    Abstract: Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.
    Type: Grant
    Filed: January 28, 2015
    Date of Patent: June 12, 2018
    Assignees: UNITY BIOTECHNOLOGY, INC., BUCK INSTITUTE FOR RESEARCH ON AGING, THE JOHN HOPKINS UNIVERSITY, MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
    Inventors: Remi-Martin Laberge, Judith Campisi, Albert Davalos, Marco Demaria, Nathaniel David, Alain Philippe Vasserot, James L. Kirkland, Tamar Tchkonia, Jan M. A. van Deursen, Jennifer Elisseeff, Chaekyu Kim, Okhee Jeon, Yi Zhu
  • Patent number: 9980962
    Abstract: Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.
    Type: Grant
    Filed: July 12, 2017
    Date of Patent: May 29, 2018
    Assignees: UNITY BIOTECHNOLOGY, INC, BUCK INSTITUTE FOR RESEARCH ON AGING, MAYO FOUNDATION FOR MEDICAL EDUCATIOIN AND RESEARCH
    Inventors: Remi-Martin Laberge, Judith Campisi, Marco Demaria, Nathaniel David, Darren J. Baker, James L. Kirkland, Tamar Tchkonia, Jan M. A. van Deursen, Yi Zhu
  • Publication number: 20180139939
    Abstract: This disclosure provides non-human animal models for age-related disorders and age-sensitive traits, particularly those caused by senescence-inducing stimuli, wherein the models comprise transgenes selectively expressed by senescent cells. The disclosure further provides methods for identifying therapeutic agents effective for treating or preventing age-related disorders and age-sensitive traits using the animal models, therapeutic agents identified using such methods, pharmaceutical compositions comprising the identified therapeutic agents, and methods of treating or preventing age-related disorders and age-sensitive traits.
    Type: Application
    Filed: January 12, 2018
    Publication date: May 24, 2018
    Inventors: Marco Demaria, Francis Rodier, Remi-Martin Laberge, Judith Campisi
  • Publication number: 20180117038
    Abstract: Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.
    Type: Application
    Filed: November 30, 2017
    Publication date: May 3, 2018
    Inventors: Remi-Martin Laberge, Judith Campisi, Marco Demaria, Nathaniel David, Alain Philippe Vasserot, James L. Kirkland, Tamar Tchkonia, Yi Zhu
  • Patent number: 9901081
    Abstract: This invention provides a transgenic mouse with a p16INK4a promoter sequence that controls expression of a protein such that it is expressed preferentially in senescent cells. The protein either directly induces apoptosis, or converts a prodrug to a cytotoxic compound. In addition, the mouse is injected with syngeneic tumor cells, or has second transgene that causes tumors to form. Removing senescent cells from the mouse may result in the formation of fewer tumors.
    Type: Grant
    Filed: March 25, 2016
    Date of Patent: February 27, 2018
    Assignees: Buck Institute for Research on Aging, Erasmus University Medical Center Rotterdam
    Inventors: Judith Campisi, Marco Demaria, Francis Rodier, Remi-Martin Laberge, James Mitchell, Jan H. J. Hoeijmakers, Wendy Toussaint
  • Patent number: 9901080
    Abstract: This invention provides a transgenic mouse for studying the role of senescent cells on an age-related disorder or an age-sensitive trait. The transgene contains a p16 promoter sequence that controls expression of an enzyme so as to cause the enzyme to be expressed in senescent cells in the mouse. The enzyme converts a prodrug to a cytotoxic agent, so that treating the mouse with the prodrug results in the prodrug selectively killing the senescent cells. As a result, progression of an age-related disorder or an age-sensitive trait is delayed. Included is the 3MR mouse model, which also expresses bioluminescent and fluorescent markers under control of the p16 promoter so that senescent cells in the mice can be visualized.
    Type: Grant
    Filed: March 11, 2016
    Date of Patent: February 27, 2018
    Assignees: Buck Institute for Research on Aging, Erasmus University Medical Center Rotterdam
    Inventors: Judith Campisi, Marco Demaria, Remi-Martin Laberge, Francis Rodier, James Mitchell, Jan H. J. Hoeijmakers, Wendy Toussaint
  • Patent number: 9884065
    Abstract: Methods are provided herein for enhancing the effectiveness of medical therapies by administering agents that suppress a biological damage response that is inducible by the medical therapy administered to a subject. In certain embodiments, a method is provided for administering an anti-senescent cell agent that suppresses a biological response comprising cellular senescence that is induced by the medical therapy.
    Type: Grant
    Filed: March 22, 2016
    Date of Patent: February 6, 2018
    Assignee: Buck Institute for Research on Aging
    Inventors: Judith Campisi, Remi-Martin Laberge, Francis Rodier, Marco Demaria
  • Patent number: 9855266
    Abstract: Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.
    Type: Grant
    Filed: March 23, 2017
    Date of Patent: January 2, 2018
    Assignees: Unity Biotechnology, Inc., Buck Institute for Research on Aging, Mayo Foundation for Medical Education and Research, The John Hopkins University
    Inventors: Remi-Martin Laberge, Judith Campisi, Albert Davalos, Marco Demaria, Nathaniel David, Alain Philippe Vasserot, James L. Kirkland, Tamar Tchkonia, Jennifer Elisseeff, Chaekyu Kim, Okhee Jeon, Yi Zhu
  • Patent number: 9849128
    Abstract: Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.
    Type: Grant
    Filed: March 10, 2017
    Date of Patent: December 26, 2017
    Assignees: Unity Biotechnology, Inc., Buck Institute for Research on Aging, Mayo Foundation for Medical Education and Research, The John Hopkins University
    Inventors: Remi-Martin Laberge, Judith Campisi, Albert Davalos, Marco Demaria, Nathaniel David, Alain Philippe Vasserot, James L. Kirkland, Tamar Tchkonia, Yi Zhu, Jennifer Elisseeff, Chaekyu Kim, Okhee Jeon
  • Publication number: 20170348307
    Abstract: Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.
    Type: Application
    Filed: July 12, 2017
    Publication date: December 7, 2017
    Inventors: Remi-Martin Laberge, Judith Campisi, Albert Davalos, Marco Demaria, Nathaniel David, Alain Philippe Vasserot, Darren J. Baker, Bennett G. Childs, James L. Kirkland, Tamar Tchkonia, Jan M.A. van Deursen, Jennifer Elisseeff, Chaekyu Kim, Okhee Jeon, Allyson K. Palmer
  • Publication number: 20170326136
    Abstract: This disclosure provides a technology for managing the sensation of pain in a subject in need thereof. Treatment methods according to this invention include administering to the subject a formulation that contains an effective amount of (4-[(4S,5R)-4,5-bis(4-chlorophenyl)-4,5-dihydro-2-[4-methoxy-2-(1-methylethoxy)phenyl]-1H-imidazol-1-yl]carbonyl]-2-piperazinone).
    Type: Application
    Filed: April 6, 2017
    Publication date: November 16, 2017
    Inventors: Nathaniel David, Albert Davalos, Remi-Martin Laberge, Judith Campisi, Marco Demaria, Alain Vasserot, Chaekyu Kim, Okhee Jeon, Jennifer Elisseeff